The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer’s disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Damage to noradrenergic neurons in the Locus coeruleus (LC) occurs contributes to neuropathology and behavioral deficits in Alzheimer's disease (AD); methods to reduce LC damage may therefore be of benefit. We previously showed that vindeburnol, a derivative of the plant alkaloid vincamine, reduced neuroinflammation, amyloid burden, and LC damage in a mouse model of AD; however, effects on behavior were not tested. We now tested the effects of vindeburnol on anxiety-like behavior in 5xFAD mice which develop robust amyloid burden at early ages. During novel object recognition testing, we observed that 5xFAD mice spent more time exploring than wildtype littermates, and that time was reduced by vindeburnol. Vindeburnol also reduced hyperlocomotion in the 5xFAD mice which may have contributed to their increased exploration times. In an open field test, vindeburnol normalized the increase of time spent in the center, and the decrease of time spent near the walls in 5xFAD mice. Vindeburnol reduced amyloid burden in the hippocampus and cortex, areas that contribute to regulation of anxiety-like behavior. In vitro, vindeburnol increased neuronal BDNF expression in a cAMP-dependent manner; and inhibited phosphodiesterase activity with an EC50 near 50 μM. These findings suggest that cAMP-mediated increases in neurotrophic factors contribute to beneficial effects of vindeburnol within the context of LC damage, which may be of value for treatment of some neuropsychiatric symptoms of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Ca2+ Influx Regulates BDNF Transcription by a CREB Family Transcription Factor-Dependent Mechanism
Tao, X., Finkbeiner, S., Arnold, D. B., Shaywitz, A. J., & Greenberg, M. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)81010-7 · Cited by 1,561
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
Ohno, M., Cole, S. L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J. F., & Vassar, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.008 · Cited by 290
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Chung, J. A., & Cummings, J. L. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70228-0 · Cited by 174
Molecular control of locus coeruleus neurotransmission
Nestler, E. J., Alreja, M., & Aghajanian, G. K. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00158-4 · Cited by 155
Richard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143120 · Cited by 142
Chalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I., & Weinshenker, D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1483-17.2017 · Cited by 136
Melia, K. R., Rasmussen, K., Terwilliger, R. Z., Haycock, J. W., Nestler, E. J., & Duman, R. S. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09748.x · Cited by 133
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease
Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., & Feinstein, D. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.012 · Cited by 116
Abnormal vibrissa‐related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics
Flanigan, T. J., Xue, Y., Kishan Rao, S., Dhanushkodi, A., & McDonald, M. P. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12133 · Cited by 104
Cited by
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200785 · Cited by 549
Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model
Sil, A., Erfani, A., Lamb, N., Copland, R., Riedel, G., & Platt, B. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-210523 · Cited by 109
Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia
Leanza, G., Gulino, R., & Zorec, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00254 · Cited by 54
“, 2009), possibly due to a poor effectiveness of the NA uptake inhibitor on LC which is already severely depleted of its neurons as a result of the disease (Braun et al., 2014; Braun and Feinstein, 2017).”
Background
Metadata
- Authors
- Braun, D., & Feinstein, D. L.
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 1702
- Pages
- 29-37
- ISSN
- 0006-8993 (ISSN-L)
- OpenAlex
- W2780656715
- Cited by
- 36
- References
- 12
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.